Gastrointestinal Cancers

Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer Demonstrates Clinical Efficacy
Gastrointestinal Cancers
Web Exclusives
Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response.
Read More
Navigating Patients Diagnosed with Complex Gastrointestinal Cancers
By Sari Francis, MSN, RN, CGRN; Veronica Campos, DNP, MSN, RN, NE-BC, OCN
Gastrointestinal Cancers, Navigation
January 2021 Vol 12, No 1
Navigation services can improve timeliness to treatment and the patient experience – an important factor for patients during a vulnerable time in their lives.
Read More

Page 3 of 3

Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?